Mohammad A Mandegar1, Nathaniel Huebsch2, Ekaterina B Frolov3, Edward Shin3, Annie Truong3, Michael P Olvera3, Amanda H Chan3, Yuichiro Miyaoka3, Kristin Holmes3, C Ian Spencer3, Luke M Judge2, David E Gordon4, Tilde V Eskildsen5, Jacqueline E Villalta6, Max A Horlbeck6, Luke A Gilbert6, Nevan J Krogan4, Søren P Sheikh5, Jonathan S Weissman6, Lei S Qi7, Po-Lin So3, Bruce R Conklin8. 1. Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA. Electronic address: mo.mandegar@gladstone.ucsf.edu. 2. Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94158, USA. 3. Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA. 4. Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; California Institute for Quantitative Biosciences, QB3, University of California, San Francisco, San Francisco, CA 94158, USA; Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA. 5. Department of Cardiovascular and Renal Research, University of Southern Denmark, 5000 Odense C, Denmark; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, 5000 Odense C, Denmark. 6. Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; California Institute for Quantitative Biosciences, QB3, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA; Center for RNA Systems Biology, University of California, San Francisco, San Francisco, CA 94158, USA. 7. Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. 8. Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; California Institute for Quantitative Biosciences, QB3, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Medicine and Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: bconklin@gladstone.ucsf.edu.
Abstract
Developing technologies for efficient and scalable disruption of gene expression will provide powerful tools for studying gene function, developmental pathways, and disease mechanisms. Here, we develop clustered regularly interspaced short palindromic repeat interference (CRISPRi) to repress gene expression in human induced pluripotent stem cells (iPSCs). CRISPRi, in which a doxycycline-inducible deactivated Cas9 is fused to a KRAB repression domain, can specifically and reversibly inhibit gene expression in iPSCs and iPSC-derived cardiac progenitors, cardiomyocytes, and T lymphocytes. This gene repression system is tunable and has the potential to silence single alleles. Compared with CRISPR nuclease (CRISPRn), CRISPRi gene repression is more efficient and homogenous across cell populations. The CRISPRi system in iPSCs provides a powerful platform to perform genome-scale screens in a wide range of iPSC-derived cell types, dissect developmental pathways, and model disease.
Developing technologies for efficient and scalable disruption of gene expression will provide powerful tools for studying gene function, developmental pathways, and disease mechanisms. Here, we develop clustered regularly interspaced short palindromic repeat interference (CRISPRi) to repress gene expression in human induced pluripotent stem cells (iPSCs). CRISPRi, in which a pan class="Chemical">doxycycline-inducible deactivated Cas9 is fused to a KRAB repression domain, can specifically and reversibly inhibit gene expression in iPSCs and iPSC-derived cardiac progenitors, cardiomyocytes, and T lymphocytes. This gene repression system is tunable and has the potential to silence single alleles. Compared with CRISPR nuclease (CRISPRn), CRISPRi gene repression is more efficient and homogenous across cell populations. The CRISPRi system in iPSCs provides a powerful platform to perform genome-scale screens in a wide range of iPSC-derived cell types, dissect developmental pathways, and model disease.
Authors: Tenneille E Ludwig; Veit Bergendahl; Mark E Levenstein; Junying Yu; Mitchell D Probasco; James A Thomson Journal: Nat Methods Date: 2006-08 Impact factor: 28.547
Authors: Angelo Lombardo; Daniela Cesana; Pietro Genovese; Bruno Di Stefano; Elena Provasi; Daniele F Colombo; Margherita Neri; Zulma Magnani; Alessio Cantore; Pietro Lo Riso; Martina Damo; Oscar M Pello; Michael C Holmes; Philip D Gregory; Angela Gritti; Vania Broccoli; Chiara Bonini; Luigi Naldini Journal: Nat Methods Date: 2011-08-21 Impact factor: 28.547
Authors: Yuichiro Miyaoka; Amanda H Chan; Luke M Judge; Jennie Yoo; Miller Huang; Trieu D Nguyen; Paweena P Lizarraga; Po-Lin So; Bruce R Conklin Journal: Nat Methods Date: 2014-02-09 Impact factor: 28.547
Authors: Ruilin Tian; Mariam A Gachechiladze; Connor H Ludwig; Matthew T Laurie; Jason Y Hong; Diane Nathaniel; Anika V Prabhu; Michael S Fernandopulle; Rajan Patel; Mehrnoosh Abshari; Michael E Ward; Martin Kampmann Journal: Neuron Date: 2019-08-15 Impact factor: 17.173
Authors: Yicheng Long; Taeyoung Hwang; Anne R Gooding; Karen J Goodrich; John L Rinn; Thomas R Cech Journal: Nat Genet Date: 2020-07-06 Impact factor: 38.330
Authors: S John Liu; Max A Horlbeck; Seung Woo Cho; Harjus S Birk; Martina Malatesta; Daniel He; Frank J Attenello; Jacqueline E Villalta; Min Y Cho; Yuwen Chen; Mohammad A Mandegar; Michael P Olvera; Luke A Gilbert; Bruce R Conklin; Howard Y Chang; Jonathan S Weissman; Daniel A Lim Journal: Science Date: 2016-12-15 Impact factor: 47.728
Authors: Luke M Judge; Juan A Perez-Bermejo; Annie Truong; Alexandre Js Ribeiro; Jennie C Yoo; Christina L Jensen; Mohammad A Mandegar; Nathaniel Huebsch; Robyn M Kaake; Po-Lin So; Deepak Srivastava; Beth L Pruitt; Nevan J Krogan; Bruce R Conklin Journal: JCI Insight Date: 2017-07-20
Authors: James D Moody; Shiri Levy; Julie Mathieu; Yalan Xing; Woojin Kim; Cheng Dong; Wolfram Tempel; Aaron M Robitaille; Luke T Dang; Amy Ferreccio; Damien Detraux; Sonia Sidhu; Licheng Zhu; Lauren Carter; Chao Xu; Cristina Valensisi; Yuliang Wang; R David Hawkins; Jinrong Min; Randall T Moon; Stuart H Orkin; David Baker; Hannele Ruohola-Baker Journal: Proc Natl Acad Sci U S A Date: 2017-09-01 Impact factor: 11.205